| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | F7 |
| Uniprot No | Q969X2 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-333aa |
| 氨基酸序列 | MACSRPPSQCEPTSLPPGPPAGRRHLPLSRRRREMSSNKEQRSAVFVILFALITILILYSSNSANEVFHYGSLRGRSRRPVNLKKWSITDGYVPILGNKTLPSRCHQCVIVSSSSHLLGTKLGPEIERAECTIRMNDAPTTGYSADVGNKTTYRVVAHSSVFRVLRRPQEFVNRTPETVFIFWGPPSKMQKPQGSLVRVIQRAGLVFPNMEAYAVSPGRMRQFDDLFRGETGKDREKSHSWLSTGWFTMVIAVELCDHVHVYGMVPPNYCSQRPRLQRMPYHYYEPKGPDECVTYIQNEHSRKGNHHRFITEKRVFSSWAQLYGITFSHPSWT |
| 预测分子量 | 38 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3条关于F7(凝血因子VII)重组蛋白的参考文献示例(内容基于学术文献概括，非真实文献)：
---
1. **文献名称**：*Production and characterization of recombinant human Factor VII in mammalian cell culture*
**作者**：Hedner, U., & Kisiel, W.
**摘要**：该研究描述了利用中国仓鼠卵巢(CHO)细胞表达系统生产重组人凝血因子VII(rFVII)的方法，并对其生物活性、糖基化修饰及止血功能进行了体外和动物模型评估，证明其与天然因子VII具有相似的功能特性。
---
2. **文献名称**：*Clinical efficacy of recombinant activated Factor VII in patients with hemophilia and inhibitors*
**作者**：Lusher, J.M., et al.
**摘要**：通过多中心临床试验评估重组活化因子VII(rFVIIa)在血友病伴抑制物患者中的止血效果。结果显示，rFVIIa可有效控制急性出血事件，且未出现严重不良反应，为抑制物患者的替代治疗提供了新选择。
---
3. **文献名称**：*Mechanism of action of recombinant Factor VIIa: A structural and functional perspective*
**作者**：Roberts, H.R., & Monroe, D.M.
**摘要**：结合晶体结构分析和功能实验，探讨了rFVIIa通过组织因子依赖和非依赖途径激活凝血级联反应的分子机制，强调其在高局部浓度下直接激活血小板表面因子X的作用。
---
4. **文献名称**：*Optimization of recombinant Factor VII production using fed-batch bioreactor systems*
**作者**：Persson, E., et al.
**摘要**：研究通过优化补料分批培养工艺提高CHO细胞中rFVII的产量，分析关键参数(如培养基成分、pH、溶解氧)对蛋白表达和活性的影响，最终实现工业化规模的高效生产。
---
注：以上文献信息为模拟概括，实际引用时需核实真实文献来源及细节。
**Background of Recombinant F7 Protein**
Recombinant F7 protein, a laboratory-engineered version of human coagulation Factor VII, is a critical therapeutic agent in managing bleeding disorders, particularly hemophilia with inhibitors. Factor VII, a vitamin K-dependent glycoprotein, naturally circulates in the blood as a zymogen and plays a pivotal role in initiating the extrinsic coagulation pathway by binding tissue factor (TF) at injury sites. Upon activation, Factor VIIa forms a complex with TF, triggering a cascade that leads to fibrin clot formation and hemostasis.
The development of recombinant F7 (rF7. e.g., NovoSeven®) emerged in the 1990s to address limitations in traditional treatments for hemophilia. Patients with inhibitors (neutralizing antibodies against Factor VIII or IX) showed poor responses to replacement therapies, necessitating alternative approaches. Using Chinese Hamster Ovary (CHO) or baby hamster kidney (BHK) cell lines, rF7 is produced via recombinant DNA technology, ensuring high purity and avoiding human plasma-derived risks like viral transmission.
Clinically, rF7a is administered intravenously to bypass deficient coagulation factors in hemophilia, offering rapid hemostasis in acute bleeding episodes, surgical settings, or prophylactic use. Its off-label applications extend to trauma-induced coagulopathy, platelet dysfunction, and other rare bleeding disorders. However, challenges include short half-life (2–3 hours), requiring repeated dosing, and thrombotic risks at high doses.
Ongoing research focuses on engineered variants with prolonged activity, reduced immunogenicity, and oral formulations. As a milestone in biopharmaceutical innovation, rF7 exemplifies the intersection of molecular biology and clinical hematology, transforming care for complex bleeding conditions.
×
